Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity

Published:2024-02-21 Issue:3 Volume:41 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

You Qiang,Li Rong,Yao Jia,Zhang Ying-Cai,Sui Xin,Xiao Cui-Cui,Zhang Jie-Bin,Xiao Jia-Qi,Chen Hai-Tian,Li Hua,Zhang Jian,Zheng Jun^ORCID,Yang Yang

Funder

National Bioengineering Research Center Cultivation Platform

National Natural Science Foundation of China

Science and Technology Program of Guangdong Province

Science and Technology Program of Guangzhou City

Natural Science Foundation of Guangdong Province

Guangdong Basic and Applied Basic Research Foundation

Guangzhou Basic and Applied Basic Research Foundation

Major talent project cultivation plan project

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12032-023-02295-0.pdf

Reference117 articles.

1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–34.

2. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459–65.

3. Lenvatinib approved for certain thyroid cancers, Cancer Discov 5(4) (2015) 338

4. FDA approves drug combo for kidney cancer, Cancer Discov 6(7) (2016) 687–688.

5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial;Frontiers in Oncology;2024-07-30

2. Strategies to enhance the response of liver cancer to pharmacological treatments;American Journal of Physiology-Cell Physiology;2024-07-01

3. Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis;Heliyon;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3